VXRT 0,96$ (-36%)
Seite 1 von 17
Neuester Beitrag: 03.12.22 09:36
|Eröffnet am:||09.04.19 16:10||von: Vassago||Anzahl Beiträge:||421|
|Neuester Beitrag:||03.12.22 09:36||von: Banani||Leser gesamt:||98.853|
|Seite: < 1 | 2 | 3 | 4 | 15 | 16 | 17 17 >|
Vassago: VXRT 0,96$ (-36%)
Ist hier halt hochspekulativ, Daumen drücken ist angesagt!
Banani: Wir sehen
Banani: Vaxart Looks to Oral Vaccines
Importantly, the company has also made progress on the manufacturing front with an announcement expected by year end on the progress. VXRT has the potential to be both a major player and part of the long-term vaccine solution. The stock is a buy under $15 with a target price of $30 per share.
Banani: September 13-15, 2021
Banani: Vaccine Conferences
…Susan Johnson PhD, will present at both ID Week 2021 and the 15th Vaccine Congress. Dr. Johnson will provide an update on the development of Vaxart's COVID-19 oral vaccine candidate.
Banani: Hier die offizielle News dazu
October 7, 2021 at 4:13 PM EDT
Data published in bioRxiv confirmed previous findings suggesting mucosal vaccines could reduce transmission of airborne viruses such as COVID-19 and flu more than injectable vaccines
Study suggests mucosal vaccines may protect not only vaccinated, but also unvaccinated animals
SOUTH SAN FRANCISCO, Calif., Oct. 7, 2021 /PRNewswire/ -- A Duke University-led study published in bioRxiv showed that Vaxart, Inc.'s (NASDAQ: VXRT) investigational oral tablet vaccine reduced the airborne transmission of SARS-CoV-2 virus in an animal model.
These results are consistent with those from Vaxart's Phase II human flu challenge study, which showed that Vaxart's oral tablet vaccine was better at reducing shedding than the injectable flu vaccine comparator.
A limitation of the currently approved injected COVID-19 vaccines is that airborne transmission occurs in people who have received them. The preclinical study also demonstrated that Vaxart's oral vaccine platform induces robust systemic and mucosal responses.
Researchers vaccinated hamsters orally or intranasally with Vaxart's S-only vaccine candidate and then exposed them to significant levels of the COVID-19 virus to promote vaccine breakthrough. Vaccinated hamsters cleared infectious virus in the nose and lungs quickly. Before clearing the infection, the vaccinated hamsters were exposed to unvaccinated hamsters via aerosol. The mucosally vaccinated hamsters infected fewer hamsters and created less severe clinical symptoms than did unvaccinated hamsters.
"These findings show that our vaccine candidate can reduce transmission of SARS-CoV-2, even when there is infection breakthrough in vaccinated subjects," said Dr. Sean Tucker, the study's lead author and Chief Scientific Officer at Vaxart.
"Existing injected vaccines don't always protect against viral shedding and transmission to other people. A vaccine that reduces shedding and reduces the probability of infection could make a big difference in protecting lives and public health, particularly given the large number of unvaccinated individuals. This study used the same vaccine candidate Vaxart is using in its development of an oral tablet vaccine," added Dr. Tucker.
Earlier this week, Vaxart initiated recruiting for a global Phase II clinical trial of its oral tablet COVID-19 vaccine candidate, which targets the SARS-CoV-2 viral spike (S) protein.
"Vaxart previously published data from a human influenza challenge study that demonstrated our oral flu vaccine candidate inhibited shedding of viral RNA better than injectable vaccines. The data reported provides further evidence that our oral vaccine could offer both an easier, more attractive mode of administration and potentially superior protection against respiratory viruses," said Andrei Floroiu, Vaxart's Chief Executive Officer.
The mucosal surface of the upper respiratory tract is the initial site of SARS-CoV-2 replication and the primary site of infection. Vaccines that induce robust mucosal immune responses may have the greatest impact on reduction of SARS-CoV-2 transmission. Approved COVID-19 vaccines, all of which are administered via intramuscular injection, stimulate systemic immune responses but have minimal effects on mucosal immunity.
Banani: Kurs After Hours
Banani: Business Update
SOUTH SAN FRANCISCO, Calif., Dec. 01, 2021 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) has entered into an agreement with Kindred Bioscience, Inc. (“KindredBio”) for the purchase of KindredBio’s manufacturing equipment and sublease of its GMP (Good Manufacturing Practices) manufacturing facility in Burlingame, California, giving Vaxart control of its second GMP manufacturing facility…..
…This acquisition gives us greater flexibility to manage our manufacturing needs by allowing Vaxart to exercise more control over our quality control program and the timing of our manufacturing activities,” said Andrei Floroiu, Vaxart’s Chief Executive Officer.
Banani: Investor Presentation January 2022
Banani: booster study
Read more at:
Banani: Funktionierender Link im Tweet zum
Banani: universal vaccine
Banani: Was für eine Rebound
Der hier die letzten Tage 50k gekauft und am nächsten Tag wieder verkauft hat oder sogar ausgestoppt wurde, beißt sich jetzt wohl in den Hintern.
Banani: Neue 13G Filings
State Street Corporation
February 24, 2022 at 8:30 AM EST
Newly published data demonstrates substantial cross-reactivity against multiple variants of COVID-19
S-only candidate is believed to be the first to demonstrate robust neutralizing antibody responses in mucosal sites, which is where primary infection occurs
Vaxart’s S-only candidate induced a 1000-fold increase in nasal IgA responses to the variants, which could have substantial impact on reducing community transmission
Wobei News im Moment doch schon eher zweitrangig sind.
Banani: Reports Fourth Quarter and Full Year 2021
Initial data from COVID-19 Phase II study expected in the first half of 2022 and data from several norovirus studies also expected this year
Ended 2021 with $182.7 million in cash, cash equivalents and marketable securities
Banani: Die Frage die ich mir stelle
Vaxart: A Speculative Biotech With Potential As Covid-19 Play And Oral Vaccine Platform
•Results from the phase 2 study using the oral vaccine Covid-19 treatment is expected in the 1st half of 2022.
•Vaxart's oral vaccine technology is unique and holds great potential with several advantages like easier route of administration, room temperature stability, and greater potential ability to prevent transmission.
•An oral vaccine candidate being developed for norovirus holds potential to target a market worth up to $10 billion in the United States alone.
•An oral vaccine candidate being developed for influenza holds potential to target a market worth up to $5 billion in the United States alone.
•I do much more than just articles at Biotech Analysis Central: Members get access to model portfolios, regular updates, a chat room, and more.
…. That means it expects it has enough cash until at least February of 2023. I believe it can tap into the ATM it has for the time being unless it really needs to raise a substantial amount of cash for another purpose. If it does intend to do another type of cash raise, then I believe it would happen before the end of this year.
Banani: Nasal sprays and pills could be game-changer
Nasal sprays and pills could be 'game-changer' in future fight against Covid-19
...Vaxart, a US-based biotech company, was working on an oral vaccine for norovirus when the pandemic started, and it had already worked out how to protect a vaccine from gastric acids and get it into the gut lining.
This technology was adapted for coronavirus and results of Phase II trials of their oral Covid-19 vaccine are due any day.
Preliminary studies show it activates IgA antibodies in both the nose and the bloodstream, as well as a stronger T-cell response. It also reduces viral shedding and infections.
Vaxart’s Chief Scientific Officer, Dr Sean Tucker, says: “By providing broader immunity we can reduce the potential for new variants.
An oral tablet vaccine could transform how the world is protected from Covid-19 and other infections because they are easy to distribute and administer.”
He adds: “There are big advantages for vaccination programmes because it doesn’t require storage at very cold temperatures and anyone can administer a pill.”
Another potential plus is getting vaccines to people who are frightened of needles. Research has confirmed that despite the risks associated with contracting Covid-19, this is a barrier for one in 10 people in the UK.
Banani: Collaborative Funding
Funding and support provided by Bill & Melinda Gates Foundation
Study will focus on determining the ability of oral vaccine tablets to induce breast milk antibodies and transfer of antibodies to young infants...